St. Agnes Hospital

Baltimore, Maryland 60045

2 studies enrolling now · 24 studies all time

What they study most

ADH Inappropriate, Acute Coronary Syndrome (ACS), Angina Pectoris, Atrial Fibrillation, Breast Cancer, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, Coronary Arteriosclerosis, DCIS

Studies at this site

• A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy — Recruiting now
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) — Completed
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) — Completed
• Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus — Stopped early
• The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus — Completed
• Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States — Completed
• Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer — Completed
• BHS5 - Testing the Effectiveness of the Exercise Plus Program — Completed
• Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) — Stopped early
• An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis — Completed
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib — Stopped early
• An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment — Completed
• SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients — Completed
• Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL — Stopped early
• A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation — Stopped early
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma — Stopped early
• Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery — Completed
• Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer — Completed
• Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer — Status unconfirmed
• MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ — Completed
• Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) — Stopped early
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia — NO_LONGER_AVAILABLE
• Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement — Completed